Sintx Technologies(US:SINT) Globenewswireยท2025-09-08 11:00Core Viewpoint - SINTX Technologies has received a Notice of Allowance from the USPTO for its patent on "Antipathogenic Fibrous Materials," which provides broad protection for its silicon nitride-based platform aimed at neutralizing pathogens [1][2][3] Intellectual Property Milestone - The patent secures extensive protection for silicon nitride's use in various applications, including medical devices, surgical care, and healthcare infrastructure, within a global infection-prevention market projected to exceed $30 billion annually [2][4] - This milestone enhances SINTX's intellectual property portfolio, complementing existing patents on antipathogenic face masks and systems for rapid viral inactivation [7][8] Leadership Perspective - The CEO of SINTX emphasizes that this patent could transform silicon nitride into a platform technology for infection prevention, potentially lowering infection risks and healthcare costs while saving lives [3][10] Healthcare Impact - Healthcare-associated infections (HAIs) are a significant challenge, with 1 in 31 U.S. hospital patients affected daily, leading to tens of billions in annual costs [4][5] - Silicon nitride's ability to provide continuous, drug-free pathogen inactivation could lead to substantial savings for hospitals and improved patient outcomes [5][6] Scientific Foundation - The patent builds on over a decade of research demonstrating silicon nitride's antimicrobial properties, including its effectiveness against various coronaviruses [6][7] Commercialization Strategy - SINTX plans to pursue partnerships and licensing agreements to integrate silicon nitride into products like wound dressings and PPE, facilitating rapid market adoption without major infrastructure changes [8][9] Future Outlook - With the patent allowance, SINTX is positioned to accelerate product commercialization and expand its presence in the infection-prevention market, potentially enhancing long-term shareholder value [9][10]